RESUMO
OBJECTIVES: The objective of this research was to evaluate the efficacy of a new antifungal imidazole, dapaconazole tosylate, in the treatment of Pityriasis versicolor (PV). DESIGN AND METHODS: Sixty patients with clinical and mycological diagnosis of PV were randomly assigned to receive either 1 g dapaconazole tosylate 2% cream or 1 g ketoconazole 2% cream. Treatments were applied once a day for 28 days. A dermatologist evaluated efficacy and safety daily, and weekly laboratorial tests were performed. The primary end point was a clinical and mycological cure of lesions after 28 days of treatment. The secondary end point was the time to clinical healing assessed by Kaplan-Meier analysis and Log-rank testing. RESULTS: Fifty-three patients adhered to protocol rules. Clinical and mycological cure was achieved in 84.6% (22/26) and 92.6% (25/27) of patients treated with ketoconazole and dapaconazole, respectively (difference [effect size] = 8.0%, Standard error of difference: 8.69%, 95% CI: -6.3 to 22.3%). Median time to healing was 23.5 and 21 days for ketoconazole and dapaconazole, respectively (p = 0.126). Adverse events occurred only in ketoconazole-treated patients (13%; 4/30). CONCLUSION: Dapaconazole tosylate is non-inferior to ketoconazole when used at a dose of 20 mg/day for 28 consecutive days for the treatment of PV. Dapaconazole also demonstrated a good safety profile.
Assuntos
Imidazóis/uso terapêutico , Cetoconazol/uso terapêutico , Tinha Versicolor/tratamento farmacológico , Administração Cutânea , Adolescente , Adulto , Antifúngicos/administração & dosagem , Antifúngicos/efeitos adversos , Antifúngicos/uso terapêutico , Método Duplo-Cego , Feminino , Humanos , Imidazóis/administração & dosagem , Imidazóis/efeitos adversos , Cetoconazol/administração & dosagem , Cetoconazol/efeitos adversos , Masculino , Pessoa de Meia-Idade , Tinha Versicolor/patologia , Resultado do Tratamento , Adulto JovemRESUMO
Dermatite seborreica (DS) é uma afecção comum da pele, caracterizada por lesões eritêmato-descamativas que afetam principalmente o couro cabeludo e a face. Sua prevalência em populações sadias varia de 2% a 5%, segundo diferentes estudos. Acomete ambos os sexos, sendo mais comum em homens. As lesões se desenvolvem em áreas ricas em glândulas sebáceas, como couro cabeludo, face, pavilhão auricular, flexuras e tórax.A dermatite seborreica da face acomete sobrancelhas, base dos cílios, pregas nasolabiais e o canal auditivo externo e pode ser tratada com corticoide tópico, metronidazol e antifúngicos tópicos, sendo o cetoconazol o principal.